Paclitaxel efficacy is increased by parthenolide via nuclear factor-kappaB pathways in In Vitro and In Vivo human non-small cell lung cancer models

Current Cancer Drug Targets

Volumn 10, Issue 7, 2010, Pages 705-715

  Gao, Z W ^a,b   Zhang, D L ^c   Guo, C B ^b  

^a LINYI PEOPLE'S HOSPITAL   (China)

^b CHILDREN S HOSPITAL OF CHONGQING MEDICAL UNIVERSITY   (China)

^c QINGDAO UNIVERSITY   (China)

Author keywords

Caspase dependent; IKK; NF B; Synergy

Indexed keywords

I KAPPA B KINASE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; PACLITAXEL; PARTHENOLIDE;

ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG POTENTIATION; DRUG TOLERABILITY; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; LUNG NON SMALL CELL CANCER; MITOCHONDRION; MODULATION; MOUSE; NONHUMAN; SIGNAL TRANSDUCTION; SYSTEMATIC REVIEW; TUMOR XENOGRAFT;

EID: 77956115773     PISSN: 15680096     EISSN: None     Source Type: Journal    
DOI: 10.2174/156800910793605776     Document Type: Article

References (51)

1. Huisman, C.; Ferreira, C. G.; Bröker, L. E.; Rodriguez, J. A.; Smit, E. F.; Postmus, P. E.; Kruyt, F. A.; Giaccone, G. Paclitaxel triggers cell death primarily via caspase-independent routes in the non-small cell lung cancer cell line NCI-H460. Clin. Cancer Res. 2002, 8, 596-606.
2. Zhang, Z.; Ma, J.; Li, N.; Sun, N.; Wang, C. Expression of nuclear factor-kappaB and its clinical significance in nonsmall-cell lung cancer. Ann Thorac Surg. 2006, 82, 243-248.
3. Jones, D. R.; Broad, R. M.; Madrid, L. V.; Baldwin, A. S. Jr.; Mayo, M. W. Inhibition of NF-kappaB sensitizes non-small cell lung cancer cells to chemotherapy-induced apoptosis. Ann. Thorac Surg. 2000, 70, 930-936.
4. Jin, X.; Lin, Q.; Zhang, D.; Zhang, M.; Wang, Z.; Guo, Z.; Peng, M.; Deng, C.; Guo, C. Chemosensitization in non-small cell lung cancer cells by IKK inhibitor occurs via NF-kappaB and mitochondrial cytochrome c cascade. J. Cell Mol. Med. 2009, 13, 4596-4607.
5. Pahl, H. L. Activators and target genes of Rel/NF-kappaB transcription factors. Oncogene 1999, 18, 6853-6866.
6. Kim, H. J.; Hawke, N.; Baldwin, A. S. NF-kappaB and IKK as therapeutic targets in cancer. Cell Death Differ. 2006, 13, 738-747.
7. Kimura, A.; Ohmichi, M.; Kawagoe, J.; Kyo, S.; Mabuchi, S.; Takahashi, T.; Ohshima, C.; Arimoto-Ishida, E.; Nishio, Y.; Inoue, M.; Kurachi, H.; Tasaka, K.; Murata, Y. Induction of hTERT expression and phosphorylation by estrogen via Akt cascade in human ovarian cancer cell lines. Oncogene 2004, 23, 4505-4515.
8. Mabuchi, S.; Ohmichi, M.; Nishio, Y.; Hayasaka, T.; Kimura, A.; Ohta, T.; Saito, M.; Kawagoe, J.; Takahashi, K.; Yada-Hashimoto, N.; Sakata, M.; Motoyama, T.; Kurachi, H.; Tasaka, K.; Murata, Y. Inhibition of NFkappaB increases the efficacy of cisplatin in in vitro and in vivo ovarian cancer models. J. Biol. Chem. 2004, 279, 23477-23485.
9. Fujioka, S.; Sclabas, G. M.; Schmidt, C.; Frederick, W. A.; Dong, Q. G.; Abbruzzese, J. L.; Evans, D. B.; Baker, C.; Chiao, P. J. Function of nuclear factor kappaB in pancreatic cancer metastasis. Clin. Cancer Res. 2003, 9, 346-354.
10. Montagut, C.; Tusquets, I.; Ferrer, B.; Corominas, J. M.; Bellosillo, B.; Campas, C.; Suarez, M.; Fabregat, X.; Campo, E.; Gascon, P.; Serrano, S.; Fernandez, P. L.; Rovira, A.; Albanell, J. Activation of nuclear factor-kappa B is linked to resistance to neoadjuvant chemotherapy in breast cancer patients. Endocr. Relat. Cancer 2006, 13, 607-616.
11. Fradet, V.; Lessard, L.; Bégin, L. R.; Karakiewicz, P.; Masson, A. M.; Saad, F. Nuclear factor-kappaB nuclear localization is predictive of biochemical recurrence in patients with positive margin prostate cancer. Clin. Cancer Res. 2004, 10, 8460-8464.
12. Zhang, D.; Jin, X.; Wang, F.; Wang, S.; Deng, C.; Gao, Z.; Guo, C. Combined prognostic value of both RelA and IkappaB-alpha expression in human non-small cell lung cancer. Ann. Surg. Oncol. 2007,14, 3581-3592.
13. Jiang, R.; Xia, Y.; Li, J.; Deng, L.; Zhao, L.; Shi, J.; Wang, X.; Sun, B. High expression levels of IKKalpha and IKKbeta are necessary for the malignant properties of liver cancer. Int. J. Cancer 2010,126, 1263-1274.
14. Kasperczyk, H.; La Ferla-Brühl, K.; Westhoff, M. A.; Behrend, L.; Zwacka, R. M.; Debatin, K. M.; Fulda, S. Betulinic acid as new activator of NF-kappaB: molecular mechanisms and implications for cancer therapy. Oncogene 2005, 24, 6945-6956.
15. Ralstin, M. C.; Gage, E. A.; Yip-Schneider, M. T.; Klein, P. J.; Wiebke, E. A.; Schmidt, C. M. Parthenolide cooperates with NS398 to inhibit growth of human hepatocellular carcinoma cells through effects on apoptosis and G0-G1 cell cycle arrest. Mol. Cancer Res. 2006, 4, 387-399.
16. Farhana, L.; Dawson, M. I.; Fontana, J. A. Apoptosis induction by a novel retinoid-related molecule requires nuclear factor-kappaB activation. Cancer Res. 2005, 65, 4909-4917.
17. Hehner, S. P.; Hofmann, T. G.; Dröge, W.; Schmitz, M. L. The antiinflammatory sesquiterpene lactone parthenolide inhibits NF-kappa B by targeting the I kappa B kinase complex. J. Immunol. 1999,163, 5617-5623.
18. Oka, D.; Nishimura, K.; Shiba, M.; Nakai, Y.; Arai, Y.; Nakayama, M.; Takayama, H.; Inoue, H.; Okuyama, A.; Nonomura, N. Sesquiterpene lactone parthenolide suppresses tumor growth in a xenograft model of renal cell carcinoma by inhibiting the activation of NF-kappaB. Int. J. Cancer 2007, 120, 2576-2581.
19. Kishida, Y.; Yoshikawa, H.; Myoui, A. Parthenolide, a natural inhibitor of Nuclear Factor-kappaB, inhibits lung colonization of murine osteosarcoma cells. Clin. Cancer Res. 2007, 13, 59-67.
20. Sweeney, C. J.; Mehrotra, S.; Sadaria, M. R.; Kumar, S.; Shortle, N. H.; Roman, Y.; Sheridan, C.; Campbell, R. A.; Murry, D. J.; Badve, S.; Nakshatri, H. The sesquiterpene lactone parthenolide in combination with docetaxel reduces metastasis and improves survival in a xenograft model of breast cancer. Mol. Cancer Ther. 2005,4, 1004-1012.
21. Patel, N. M.; Nozaki, S.; Shortle, N. H.; Bhat-Nakshatri, P.; Newton, T. R.; Rice, S.; Gelfanov, V.; Boswell, S. H.; Goulet, R. J. Jr.; Sledge, G. W. Jr.; Nakshatri, H. Paclitaxel sensitivity of breast cancer cells with constitutively active NF-kappaB is enhanced by IkappaBalpha super-repressor and parthenolide. Oncogene 2000, 19, 4159-4169.
22. Yip-Schneider, M. T.; Wu, H.; Ralstin, M.; Yiannoutsos, C.; Crooks, P. A.; Neelakantan, S.; Noble, S.; Nakshatri, H.; Sweeney, C. J.; Schmidt, C. M. Suppression of pancreatic tumor growth by combination chemotherapy with sulindac and LC-1 is associated with cyclin D1 inhibition in vivo. Mol. Cancer Ther. 2007, 6, 1736-1744.
23. Martello, L. A.; McDaid, H. M.; Regl, D. L.; Yang, C. P.; Meng, D.; Pettus, T. R.; Kaufman, M. D.; Arimoto, H.; Danishefsky, S. J.; Smith, A. B. 3rd.; Horwitz, S. B. Taxol and discodermolide represent a synergistic drug combination in human carcinoma cell lines. Clin. Cancer Res. 2000, 6, 1978-1987.
24. Jin, X.; Wang, Z.; Qiu, L.; Zhang, D.; Guo, Z.; Gao, Z.; Deng, C.; Wang, F.; Wang, S.; Guo, C. Potential biomarkers involving IKK/RelA signal in early stage non-small cell lung cancer. Cancer Sci. 2008, 99, 582-589.
25. Zou, Y.; Fu, H.; Ghosh, S.; Farquhar, D.; Klostergaard, J. Antitumor activity of hydrophilic Paclitaxel copolymer prodrug using locoregional delivery in human orthotopic non-small cell lung cancer xenograft models. Clin. Cancer Res. 2004, 10, 7382-7391.
26. Yip-Schneider, M. T.; Nakshatri, H.; Sweeney, C. J.; Marshall, M. S.; Wiebke, E. A.; Schmidt, C. M. Parthenolide and sulindac cooperate to mediate growth suppression and inhibit the nuclear factor-kappa B pathway in pancreatic carcinoma cells. Mol. Cancer Ther. 2005,4, 587-594.
27. Park, S. J.; Wu, C. H.; Gordon, J. D.; Zhong, X.; Emami, A.; Safa, A. R. Taxol induces caspase-10-dependent apoptosis. J. Biol. Chem. 2004, 279, 51057510-67.
28. Jones, D. R.; Broad, R. M.; Comeau, L. D.; Parsons, S. J.; Mayo, M. W. Inhibition of nuclear factor kappaB chemosensitizes non-small cell lung cancer through cytochrome c release and caspase activation. J. Thorac. Cardiovasc. Surg. 2002, 123, 310-317.
29. Mitsiades, N.; Mitsiades, C. S.; Richardson, P. G.; Poulaki, V.; Tai, Y. T.; Chauhan, D.; Fanourakis, G.; Gu, X.; Bailey, C.; Joseph, M.; Libermann, T. A.; Schlossman, R.; Munshi, N. C.; Hideshima, T.; Anderson, K. C. The proteasome inhibitor PS-341 potentiates sensitivity of multiple myeloma cells to conventional chemotherapeutic agents: therapeutic applications. Blood 2003, 101, 2377-2380.
30. Huang, G. S.; Lopez-Barcons, L.; Freeze B. S.; Smith, A. B. 3rd.; Goldberg, G. L.; Horwitz, S. B.; McDaid, H. M. Potentiation of taxol efficacy and by discodermolide in ovarian carcinoma xenograft-bearing mice. Clin. Cancer Res. 2006, 12, 298-304.
31. Morishita, R.; Tomita, N.; Kaneda, Y.; Ogihara, T. Molecular therapy to inhibit NFkappaB activation by transcription factor decoy oligonucleotides. Curr. Opin. Pharmacol. 2004, 4, 139-146.
32. Fujioka, S.; Sclabas, G. M.; Schmidt, C.; Frederick, W. A.; Dong, Q. G.; Abbruzzese, J. L.; Evans, D. B.; Baker, C.; Chiao, P. J. Function of nuclear factor kappaB in pancreatic cancer metastasis. Clin. Cancer Res. 2003, 9, 346-354.
33. Fujioka, S.; Sclabas, G. M.; Schmidt, C.; Niu, J.; Frederick, W. A.; Dong, Q. G.; Abbruzzese, J. L.; Evans, D. B.; Baker, C.; Chiao, P. J. Inhibition of constitutive NF-kappa B activity by I kappa B alpha M suppresses tumorigenesis. Oncogene 2003, 22, 1365-1370.
34. Karin, M.; Yamamoto, Y.; Wang, Q. M. The IKK NF-kappa B system: a treasure trove for drug development. Nat. Rev. Drug Discov. 2004, 3, 17-26.
35. Horton, T. M.; Pati, D.; Plon, S. E.; Thompson, P. A.; Bomgaars, L. R.; Adamson, P. C.; Ingle, A. M.; Wright, J.; Brockman, A. H.; Paton, M.; Blaney, S. M. A phase 1 study of the proteasome inhibitor bortezomib in pediatric patients with refractory leukemia: a Children's Oncology Group study. Clin. Cancer Res. 2007, 13, 1516-1522.
36. O'Connor, O. A. Targeting histones and proteasomes: new strategies for the treatment of lymphoma. J. Clin. Oncol. 2005, 23, 6429-6436.
37. Strnad, J.; Burke, J. R. IkappaB kinase inhibitors for treating auto-immune and inflammatory disorders: potential and challenges. Trends Pharmacol. Sci. 2007, 28, 142-148.
38. Wang, J.; An, H.; Mayo, M. W.; Baldwin, A. S.; Yarbrough, W. G. LZAP, a putative tumor suppressor, selectively inhibits NF-kappaB. Cancer Cell. 2007, 12, 239-251.
39. Ortiz, M. A.; Lopez-Hernandez, F. J.; Bayon, Y.; Pfahl, M.; Piedrafita, F. J. Retinoid-related molecules induce cytochrome c release and apoptosis through activation of c-Jun NH(2)-terminal kinase/p38 mitogen-activated protein kinases. Cancer Res. 2001, 61, 8504-8512.
40. Huang, Y.; Johnson, K. R.; Norris, J. S.; Fan, W. factor-kappaB/IkappaB signaling pathway may contribute to the mediation of paclitaxel-induced apoptosis in solid tumor cells. Cancer Res. 2000, 60, 4426-4432.
41. Huang, Y.; Fan, W. IkappaB kinase activation is involved in regulation of paclitaxel-induced apoptosis in human tumor cell lines. Mol. Pharmacol. 2002, 61, 105-113.
42. Cai, Z.; Körner, M.; Tarantino, N.; Chouaib, S. IkappaB alpha overexpression in human breast carcinoma MCF7 cells inhibits nuclear factor-kappaB activation but not tumor necrosis factor-alpha-induced apoptosis. J. Biol. Chem. 1997, 272, 96-101.
43. Dziadyk, J. M.; Sui, M.; Zhu, X.; Fan, W. Paclitaxel-induced apoptosis may occur without a prior G2/M-phase arrest. Anticancer Res. 2004,24, 27-36.
44. Saadane, A.; Masters, S.; DiDonato, J.; Li, J.; Berger, M. Parthenolide inhibits IkappaB kinase, NF-kappaB activation, and inflammatory response in cystic fibrosis cells and mice. Am. J. Respir. Cell. Mol. Biol. 2007, 36, 728-736.
45. Ferreira, C. G.; Span, S. W.; Peters, G. J.; Kruyt, F. A.; Giaccone, G. Chemotherapy triggers apoptosis in a caspase-8-dependent and mitochondria-controlled manner in the non-small cell lung cancer cell line NCI-H460. Cancer Res. 2000, 60, 7133-7141.
46. Bröker, L. E.; Kruyt, F. A.; Giaccone, G. Cell death independent of caspases: a review. Clin. Cancer Res. 2005, 11, 3155-3162.
47. Suvannasankha, A.; Crean, C. D.; Shanmugam, R.; Farag, S. S.; Abonour, R.; Boswell, H. S.; Nakshatri, H. Antimyeloma effects of a sesquiterpene lactone parthenolide. Clin. Cancer Res. 2008, 14, 1814-1822.
48. Zhang, D.; Qiu, L.; Jin, X.; Guo, Z.; Guo, C. Nuclear factor-kappaB inhibition by parthenolide potentiates the efficacy of Taxol in non-small cell lung cancer in vitro and in vivo. Mol. Cancer Res. 2009,7,1139-1149.
49. Ling, Y.; Zhong, Y.; Perez-Soler, R. Disruption of cell adhesion and caspase-mediated proteolysis of beta- and gamma-catenins and APC protein in paclitaxel-induced apoptosis. Mol. Pharmacol. 2001,59, 593-603.
50. Nakshatri, H.; Rice, S. E.; Bhat-Nakshatri, P. Antitumor agent parthenolide reverses resistance of breast cancer cells to tumor necrosis factor-related apoptosis-inducing ligand through sustained activation of c-Jun N-terminal kinase. Oncogene 2004, 23, 7330-7344.
51. Gray, J.; Mao, J. T.; Szabo, E.; Kelley, M.; Kurie, J.; Bepler, G.; American College of Chest Physicians. Lung cancer chemoprevention: ACCP evidence-based clinical practice guidelines (2nd Edition). Chest 2007, 132, 56S-68S.